FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions

EGFR exon 20 insertion mutations occur in approximately 2% of non-small cell lung cancer (NSCLC) and overall account for approximately 9% of all the EGFR mutations NSCLC (Robichaux et al., 2021). Current first-line (1L) standard of care (SOC) for NSCLC patients with this mutation is platinum-based chemotherapy (NCCN NSCLC, 2022). Furmonertinib (AST2818) is an oral, brain penetrant, broadly active mutant-selective EGFR inhibitor that targets EGFR exon 20 insertions and other EGFR mutations (Musib et al., NACLC 2022).